CN114007620A - 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 - Google Patents

二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 Download PDF

Info

Publication number
CN114007620A
CN114007620A CN202080032509.8A CN202080032509A CN114007620A CN 114007620 A CN114007620 A CN 114007620A CN 202080032509 A CN202080032509 A CN 202080032509A CN 114007620 A CN114007620 A CN 114007620A
Authority
CN
China
Prior art keywords
days
compound
saturated
alkylene
partially unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080032509.8A
Other languages
English (en)
Inventor
赵焰平
黄淮
王红军
姜媛媛
梁会宁
安然
兰洲
王瑾
周丽莹
刘亚男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of CN114007620A publication Critical patent/CN114007620A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Figure DDA0003329214740000011
一种生物医药领域治疗、遏制或减轻子宫内膜异位相关的疼痛的方法，其包括向需要其的个体给药治疗有效量的式(I)的二氨基嘧啶类化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N‑氧化物、同位素标记的化合物、代谢物或前药。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080032509.8A 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 Pending CN114007620A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085209 2019-04-30
CN2019085209 2019-04-30
PCT/CN2020/087689 WO2020221277A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Publications (1)

Publication Number Publication Date
CN114007620A true CN114007620A (zh) 2022-02-01

Family

ID=73028778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032509.8A Pending CN114007620A (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Country Status (12)

Country Link
US (1) US20220249478A1 (zh)
EP (1) EP3960178A4 (zh)
JP (1) JP2022531570A (zh)
KR (1) KR20220008286A (zh)
CN (1) CN114007620A (zh)
AU (1) AU2020266947A1 (zh)
BR (1) BR112021021838A8 (zh)
CA (1) CA3138238A1 (zh)
MX (1) MX2021013347A (zh)
SG (1) SG11202111960PA (zh)
TW (1) TWI737285B (zh)
WO (1) WO2020221277A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
CN108779119A (zh) * 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHAOJIE DING等: "P2X3 receptor involvement in endometriosis pain via ERK signaling pathway", PLOS ONE, vol. 12, no. 9, pages 1 - 17, XP055735113, DOI: 10.1371/journal.pone.0184647 *

Also Published As

Publication number Publication date
KR20220008286A (ko) 2022-01-20
WO2020221277A1 (zh) 2020-11-05
CA3138238A1 (en) 2020-11-05
JP2022531570A (ja) 2022-07-07
SG11202111960PA (en) 2021-12-30
BR112021021838A2 (pt) 2022-01-04
TWI737285B (zh) 2021-08-21
BR112021021838A8 (pt) 2023-02-28
TW202106303A (zh) 2021-02-16
MX2021013347A (es) 2022-01-24
EP3960178A1 (en) 2022-03-02
US20220249478A1 (en) 2022-08-11
AU2020266947A1 (en) 2021-12-16
EP3960178A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
CN111225911B (zh) 用于治疗血液病的化合物和组合物
TWI804743B (zh) 治療特發性肺纖維化的方法
US20080293777A1 (en) Weight Loss Treatment
WO2020177587A1 (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
JP2022508402A (ja) 肝障害の治療
CN114007620A (zh) 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法
JP2023508325A (ja) 組み合わせ
EP4186508A1 (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
WO2020221274A1 (zh) 二氨基嘧啶类化合物治疗咳嗽的方法
BR112015007870B1 (pt) Composição compreendendo derivado de 6-oxo-1,6-di-hidro-piridazina e inibidor de mek, e seus usos
CN109651395B (zh) 一种可靶向降解fkbp12及12.6的化合物及其制备方法和应用
JPH03215435A (ja) アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
WO2000033845A1 (fr) Agent therapeutique pour le traitement de la dyserection
AU2019260644B2 (en) Process for preparing a potent thiazole compound, pharmaceutical formulation and uses thereof
BR122023024844A2 (pt) Agentes terapêuticos anticâncer
WO2024008044A1 (zh) 大环拟肽类蛋白酶抑制剂及其用途
TW202135807A (zh) 組合
BR112017019983B1 (pt) Agentes terapêuticos anticâncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063619

Country of ref document: HK